Leidos trades at a nearly 28% discount to peer median P/E at 11.2x despite delivering record diluted EPS of $11.13 in fiscal 2025, up 21% year-over-year. Free cash flow hit $1.625B, and the company recently secured a $2.7B hypersonic weapons production contract with the U.S. Army, adding to a robust pipeline. The stock’s recent decline below its 200-day moving average ($175.97) creates an attractive entry point relative to underlying earnings power.
Insider Selling Pattern
Net insider value over 24 months is -$18.2M despite positive share count, reflecting significant disposition activity at higher prices.
Technical Downtrend Intact
Price at $128.12 remains below both the 50-day ($146.70) and 200-day MAs, with RSI at 36.6 not yet at oversold extremes.
Contract Execution Risk
New awards like the $2.7B hypersonic program carry production ramp-up and margin risk that could impact profitability.
Balance Sheet Leverage
Total debt of $5.93B against stockholders’ equity of $4.92B may pressure interest expenses if rates stay elevated.